Box 3.

Key Areas Explored in the Interviews

• Participants' clinical background, training, and experience; previous involvement (if any) in trials of HCL technology or supporting HCL users receiving routine care.

• Experiences (if any) of training study participants to use the HCL.

• Experiences of providing support to participants using a HCL during pregnancy; perceived differences in the type and amount of support required compared with people using conventional insulin regimens (e.g., CGM with pump and/or MDI); perceived sustainability of providing this level of support upon rollout.

• Perceived benefits and drawbacks of using HCL technology compared to other regimens used to manage T1D in pregnancy.

• Experiences of training and support received to deliver the trial; views about the kinds of training, support, and resources healthcare professionals will need to support HCL users in routine clinical care.

• Views about who should provide and how services should be organized or structured to deliver HCL therapy in routine clinical care.

• Perceived impact of rolling out HCL technology on healthcare professionals' clinical practice, workloads, and wider healthcare resources.